Literature DB >> 33767779

The epidemiology of myasthenia gravis.

Ana-Maria Bubuioc1, Aigerim Kudebayeva2, Saule Turuspekova3, Vitalie Lisnic1, Maurizio Angelo Leone4.   

Abstract

Neuromuscular junction (NMJ) disorders include several dysfunctions that ultimately lead to muscle weakness. Myasthenia gravis (MG) is the most prevalent NMJ disorder with a highly polymorphic clinical presentation and many different faces. Being an autoimmune disease, MG correlates with the presence of detectable antibodies directed against the acetylcholine receptor, muscle-specific kinase, lipoprotein-related protein 4, agrin, titin, and ryanodine in the postsynaptic membrane at the NMJ. MG has become a prototype serving to understand both autoimmunity and the function of the NMJ better. The aim of this review is to synthesize some of the epidemiological data available. Epidemiological data regarding MG are important for postulating hypotheses regarding its etiology and facilitating the description of MG subtypes. Thus, adequate documentation through broad databases is essential. The incidence and prevalence of MG reported around the globe have been rising steadily and consistently over the past decades. Ethnic aspects, gender-related differences, and environmental risk factors have been described, implying that these might contribute to a specific phenotype, further suggesting that MG may be considered an umbrella term that covers several clinical entities. ©2020 JOURNAL of MEDICINE and LIFE.

Entities:  

Keywords:  autoimmunity; epidemiology; incidence; myasthenia gravis; prevalence

Mesh:

Year:  2021        PMID: 33767779      PMCID: PMC7982252          DOI: 10.25122/jml-2020-0145

Source DB:  PubMed          Journal:  J Med Life        ISSN: 1844-122X


  61 in total

1.  Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years.

Authors:  Fabrizio Pallaver; Anna Pia Riviera; Silvano Piffer; Roberta Ricciardi; Riccardo Roni; Daniele Orrico; Domenico Marco Bonifati
Journal:  Neuroepidemiology       Date:  2011-07-12       Impact factor: 3.282

Review 2.  Lifetime course of myasthenia gravis.

Authors:  David Grob; Norman Brunner; Tatsuji Namba; Murali Pagala
Journal:  Muscle Nerve       Date:  2008-02       Impact factor: 3.217

3.  Estimation of incidence, prevalence, and age-at-diagnosis of myasthenia gravis among adults by hospital discharge records.

Authors:  Anett Foldvari; Nora Kovacs; Valeria Sipos; Gabriella Merth; Ferenc Vincze; Maria Szucs; Janos Sandor
Journal:  Wien Klin Wochenschr       Date:  2015-05-20       Impact factor: 1.704

4.  The autoimmune spectrum of myasthenia gravis: a Swedish population-based study.

Authors:  F Fang; O Sveinsson; G Thormar; M Granqvist; J Askling; I E Lundberg; W Ye; L Hammarström; R Pirskanen; F Piehl
Journal:  J Intern Med       Date:  2014-11-13       Impact factor: 8.989

5.  Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases.

Authors:  Ernestina Santos; Ester Coutinho; Isabel Moreira; Ana Martins Silva; Dina Lopes; Henrique Costa; Fernando Silveira; Goreti Nadais; Hugo Morais; João Martins; Maria Ceu Branco; Andreia Veiga; Rosa Santos Silva; Augusto Ferreira; Filipa Sousa; Marta Freijo; Ilda Matos; Rui André; Luís Negrão; Carla Fraga; Manuela Santos; Mafalda Sampaio; Carlos Lopes; Maria Isabel Leite; Guilherme Gonçalves
Journal:  Muscle Nerve       Date:  2016-07-04       Impact factor: 3.217

6.  Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001.

Authors:  J F Owe; A K Daltveit; N E Gilhus
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

Review 7.  Clinical evaluation and management of myasthenia gravis.

Authors:  John C Keesey
Journal:  Muscle Nerve       Date:  2004-04       Impact factor: 3.217

8.  Epidemiology of myasthenia gravis in Austria: rising prevalence in an ageing society.

Authors:  Hakan Cetin; Gerhard Fülöp; Heidemarie Zach; Eduard Auff; Fritz Zimprich
Journal:  Wien Klin Wochenschr       Date:  2012-11-06       Impact factor: 1.704

Review 9.  Complicating autoimmune diseases in myasthenia gravis: a review.

Authors:  Aliona Nacu; Jintana Bunpan Andersen; Vitalie Lisnic; Jone Furlund Owe; Nils Erik Gilhus
Journal:  Autoimmunity       Date:  2015-04-27       Impact factor: 2.815

10.  Epidemiology of Myasthenia Gravis in Sweden 2006-2016.

Authors:  Elisabet Westerberg; Anna Rostedt Punga
Journal:  Brain Behav       Date:  2020-09-01       Impact factor: 2.708

View more
  11 in total

1.  Physician-Reported Perspectives on Myasthenia Gravis in the United States: A Real-World Survey.

Authors:  Milada Mahic; Ali M Bozorg; Jonathan J DeCourcy; Keisha J Golden; Gregor A Gibson; Christian F Taylor; Angela Ting; Tyler J Story; Anna Scowcroft
Journal:  Neurol Ther       Date:  2022-07-20

2.  [Clinical and paraclinical profile of autoimmune myasthenia gravis in Ouagadougou, Burkina Faso].

Authors:  Djingri Labodi Lompo; Nagaonlé Éric Some; Adja Mariam Ouedraogo; Rodrigue P Yonli; Ousséini Diallo; Christian Napon; Athanase Millogo; Jean Kabore
Journal:  Med Trop Sante Int       Date:  2021-11-11

Review 3.  Exploring the Gut Microbiome in Myasthenia Gravis.

Authors:  Angel Yun-Kuan Thye; Jodi Woan-Fei Law; Loh Teng-Hern Tan; Sivakumar Thurairajasingam; Kok-Gan Chan; Vengadesh Letchumanan; Learn-Han Lee
Journal:  Nutrients       Date:  2022-04-14       Impact factor: 6.706

4.  Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series.

Authors:  Seung Ah Kang; Megan Sweeney; Raghav Govindarajan
Journal:  J Clin Neuromuscul Dis       Date:  2022-06-01

5.  miR-181a Ameliorates the Progression of Myasthenia Gravis by Regulating TRIM9.

Authors:  Qiang Wang; Yunquan Liu; Shixiang Kuang; Ruozhao Li; Ning Weng; Zhichao Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-09       Impact factor: 2.629

Review 6.  MicroRNA-21 Is a Versatile Regulator and Potential Treatment Target in Central Nervous System Disorders.

Authors:  Xue Bai; Zhigang Bian
Journal:  Front Mol Neurosci       Date:  2022-01-31       Impact factor: 5.639

7.  Bilateral Facial Palsy Without Ocular Muscle Involvement in Myasthenia Gravis: Case Report.

Authors:  Muhammad Umair; Filzah Faheem; Hashir Amin Malik; Syed Ahmad Ali Hassan; Athar Iqbal
Journal:  Cureus       Date:  2022-03-16

8.  Effectiveness of modified Buzhong Yiqi decoction in treating myasthenia gravis: study protocol for a series of N-of-1 trials.

Authors:  Senhui Weng; Jinghao Li; Benshu Chen; Long He; Zhuotai Zhong; Linwen Huang; Shijing Zhang; Fengbin Liu; Qilong Jiang
Journal:  Trials       Date:  2022-04-27       Impact factor: 2.728

9.  Total Plasma Exchange in Neuromuscular Junction Disorders-A Single-Center, Retrospective Analysis of the Efficacy, Safety and Potential Diagnostic Properties in Doubtful Diagnosis.

Authors:  Andreas Totzeck; Michael Jahn; Benjamin Stolte; Andreas Thimm; Christoph Kleinschnitz; Tim Hagenacker
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

10.  Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis.

Authors:  Yue Su; Zhe Ruan; Rui Wang; Sijia Hao; Yonglan Tang; Xiaoxi Huang; Ting Gao; Zhuyi Li; Ting Chang
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.